HUVEC – Human Umbilical Vein Endothelial Cells, Single Donor, in EGM™-2
HUVEC – Human Umbilical Vein Endothelial Cells, Single Donor, in EGM™-2
Cryopreserved ampule of Human Umbilical Vein Endothelial Cells (HUVEC), from a single donor, in EGMTM-2 containing ≥ 500,000 cells
Product Overview
Lonza's Cryopreserved HUVECs are shipped as frozen primaries. They are guaranteed to express CD31/105 and survive in culture through 15* population doublings (*except HUVEC-XLTM guaranteed through 5 PD).
All cells test negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C are not detected for all donors and/or cell lots. A Certificate of Analysis is provided for each cell lot purchased.
Our pooled vs. single donor options allow researchers to study or exclude donor variability from their experiments. Depending upon the study, pooled version is typically utilized to reduce donor variability while single donor option allows researchers to assess donor-specific differences.
HUVEC-XL size consists of 10 million cells/amp achieved by pooling donors. This option is designed to support studies that require large volume of cells while still offering cost-benefits to researchers.
Not All HUVECs Are Created Equal – Which Type Is Suitable for Your Research?
- C2517A (single donor), C2519A (pooled donor), 00191027 (XL size) - Isolated in EGMTM-2 Media, in presence of growth factors such as VEGF, rhFGF, rhEGF, and others. Does not contain BBE.
- C2517AS (single donor), C2519AS (pooled donor) - Pre-screened HUVECs in EGMTM-2 Media. Screened for angiogenesis markers and test positive for expression of eNOS, Axl, Tie-2 and VEGFr2.
- CC-2517 (single donor), CC-2519 (pooled donor) - Both isolated in EGMTM Media, in absence of defined growth factors. Contains BBE. No exogenous VEGF.
- CC-2935 (single donor) - Isolated in EGMTM - Plus Media: Improved version of part number CC-2517. Offers faster proliferation rates than HUVEC isolated in EGMTM Media. No exogenous VEGF.
Benefits
- Guaranteed through 15 population doublings
- Test negative for mycoplasma, bacteria, yeast, and fungi
- HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
- A Certificate of Analysis is provided for each cell lot purchased
Applications
- Wound healing
- Angiogenesis
- Tissue engineering
- Inflammation
- Oncology
- Pharmacology
- Vascular modeling
- Transfection
Storage and Content
- 1 x Cryopreserved ampule of HUVEC containing ≥ 500,000 cells
SDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
-
Primary Cells and Media Reference Guide
A comprehensive collection of Lonza primary cell and media products supporting many research areas. -
Instructions & Technical Info - Endothelial Cell Systems
Technical Information and Instructions for Proper Use of Endothelial Cells -
A Quantitative, High-throughput, Real-time Angiogenic Tube Formation Assay
Angiogenic Assay - Human Umbilical Vein Endothelial Cells and Human Dermal Fibroblasts in Co-culture
Educational Material
Brochures, White Papers etc.
-
Poster - AACR 2017
Simple and easy monitoring of tube formation and migration assays with the CytoSMART™ Live Cell Imaging System -
White Paper
Simple and easy monitoring of three different cancer-relevant assays – Tube formation assay, 2D cell migration assay and 3D cell invasion assay -
Automated Cell Signaling Assays Using Primary HUVECs
Lonza's Primary HUVECs are an excellent cell type to measure the effects of pharmacologically-important compounds on vial signaling pathways, and they provide increased data relevancy compared to cell lines. -
Expanded HUVECs for High-throughput Screening
HUVECs are a good primary endothelial cell type for many in vitro studies and also for several high-throughput screening applications. Consequently, Lonza offers, HUVEC-XL. These cells are expanded to passage-3 from pooled P1-HUVECs and packaged at 10 million cells per ampoule. -
Assessment of the Anti-angiogenic Effect of VEGFR2 siRNA in HUVEC
Scientific poster for AACR 2015 -
Assessment of the Anti-Angiogenic Effect of VEGFR2 siRNA in HUVEC Using the Nucleofector® Technology
In the White Paper we show the use of our Nucleofector® Technology to transfect single-donor Clonetics® HUVEC with siRNA directed against Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). . -
Primary Cells and Media Reference Guide
A comprehensive collection of Lonza primary cell and media products supporting many research areas. -
First siRNA Library Screening in Hard-to-Transfect HUVEC and Jurkat Cells
High throughput transfection of siRNA libraries has become a valuable tool in target identifi cation and validation. However, such screenings have so far been constrained to mostly easy-totransfect adherent cell lines. Lonza’s 96-well Shuttle® System, based on the well-established Amaxa® Nucleofector® Technology, extends these approaches to primary and diffi cult-to-transfect cells. -
Tube Formation Assay with Primary HUVECs
In this study, we have optimized this assay using Lonza's Primary HUVECs and EGM™-2 Media -
A Quantitative, High-throughput, Real-time Angiogenic Tube Formation Assay
Angiogenic Assay - Human Umbilical Vein Endothelial Cells and Human Dermal Fibroblasts in Co-culture